Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)

Danish Headache Center30 enrolled

Overview

The aim of the present study is to explore the importance of migraine phenotype on the headache/migraine responses after CGRP in FHM-patients, MA-patients and healthy volunteers.

Calcitonin gene-related peptide (CGRP) induces migraine attacks indistinguishable from spontaneous attacks in a large proportion of migraine sufferers. Treatment of spontaneous migraine attacks with an inhibitor of CGRP is effective in many patients. These data show that CGRP is involved in migraine pathophysiology. The importance of migraine genetics is disputed. Evidence from FHM patients with known mutations indicates that migraine pathways in FHM may be different from normal migraine. The aim of the present study is to examine whether this difference also exists in FHM patients without known mutations. The project will improve our understanding of the neurobiology of migraine and stimulate development of new treatment targets.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Familial Hemiplegic Migraine Migraine With Aura Healthy

Interventions

CGRPDRUG

CGRP (0.5 ug/min) infused intravenously over 20 min

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of familial hemiplegic migraine (IHS-classification criteria) * Diagnosis of migraine with aura(IHS-classification criteria) * Healthy controls Exclusion Criteria: Patients and controls: * A history of cerebrovascular disease and other CNS- disease * A history of serious somatic and mental disease * A history suggesting ischaemic heart disease * A history of hypo- or hypertension * Daily intake of medication apart from oral contraceptives * Abuse of alcohol or medicine (opioid analgesics). * Pregnant or breastfeeding women. * On the study day: * No intake of a simple analgesic in the previous 48 hours * No headache in the previous 48 hours

Locations (1)

Danish Headache Center, University of Copenhagen, Faculty of Health Sciences, Department of Neurology, Glostrup Hospital

Glostrup, Copenhagen, Denmark

Outcomes

Primary Outcomes

Migraine and associated symptoms

Time frame: 0-14 h

Secondary Outcomes

Migraine aura

Time frame: 0 - 14 h

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.